ClinicalTrials.gg
CompletedNCT04161521Updated Nov 13, 2019

Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital

An interventional study of Novel Technique of Placenta Accreta in Menoufia University Hospital in Placenta Accreta, sponsored by Menoufia Obstetrics and Gynecology Group. Completed at 2 sites in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Menoufia Obstetrics and Gynecology Group · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Nov 2018, registered Nov 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Evaluation of maternal morbidity and mortality of our novel surgical procedure for conservative management of placenta accreta in our tertiary referral institute.

Read the detailed description

A descripative cohort study which included 60 pregnant women recuirted from Obstetrics and Gynecology Department, Menoufia University Hospital and diagnosed as placenta previa accreta.

  • Ethical considerations: Ethics: The study was approved by Ethical Committee of Menoufia Faculty of Medicine.

Consent: after explanation of surgical procedure of the study, an informed written consent was obtained from all cases included in this study.

Sample size: (No= 60) Based on previous studies regarding MAP, The incidence of placenta accreta = 1/2500 , so the calculated sample size for this study was 59 which to be around 60 with confidence level 95% margin of error 5% (Pliskow S et al., 2009).

Inclusion criteria:

  1. Age between 20 - 40 years old.
  2. Gestational age between 28 - 38 weeks.
  3. Any patient diagnosed as placenta previa with ultrasound criteria of accretion.

    • Criteria of accretion by Colour Doppler ultrasound include: (Berkley et al., 2013).

      1. The presence of irregular shaped placental lacunae within the placenta.
      2. Thinning of myometrium overlying the placenta.
      3. Absence of retroplacental 'non-lucent line'.
      4. Protrusion of the placenta into the bladder.
      5. Increased vascularity of the uterine serosa-bladder interface.
      6. Turbulent blood flow through the lacunae on Doppler ultrasonography.
    • All patients were subjected to the following:

I. Detailed history taking:

  1. Personal history: name ,age, address, occupation, marietal status, number of children ,age of the youngest child, the gender of the children and special habbits of medical importance like smoking.
  2. Past history: past medical history (e.g. diabetes mellitus, hypertension, renal disease, liver disease and any systemic disease like cardiac or pulmonary diseases), past surgical history (any operation done before), blood transfusion, drugs taken and allergy from any drug.
  3. Family history: hypertension, diabetes mellitus, consanguinity.
  4. Menstrual history: LMP (the first day of last menstrual period), duration, frequency, regularity of period, presence of dysmenorrhea and EDD (the expected date of delivery).
  5. Obstetric history : gravidity, parity, number of deliveries, mode of delivery (normal vaginal delivery or cesarean delivery) , place of delivery, the reason for cesarean delivery, any operative complications, number of children and their gender , any neonatal complications, number of abortions, gestational age of them, if abortion followed by surgery like evacuation and curettage.

II. Clinical examination:

  1. General examination:

    • General condition.
    • Vital signs including blood pressure, pulse, temperature.
    • Height, weight and body mass index (BMI).
    • Neck : thyroid gland, neck veins and pulsations.
    • Chest : lung, heart, breasts.
    • Upper and lower limbs (edema , varicosities).
  2. Abdominal examination :

    1. Inspection :

      Size, shape, pigmentation (linea nigra),stria gravidarum and scars (like cesarean section scars).

    2. Palpation:

      To detect tenderness, rigidity and fundal level.

    3. Auscultation:

      Fetal heart sounds.

      III. Investigations :

      • Preoperative labaratory investigations like complete blood count (CBC), prothrombin time (PT), liver function, kidney function, virology and ECG.
      • Obstetric ultrasound:

      Fetal observation : transabdominal pelvic ultrasound was performed to detect fetal presentation, lie, viability ( by observation of fetal heart movement), gestational age by measuring biparital diameter, femur length and abdominal circumference) and fetal weight.

      Placenta observation : site (anterior or posterior), position in realtion to internal os to determine type of placenta previa and colour Doppler to determine grade of accretion ( accrete, increta, percreta and focal aacretion) and criteria of accretion.

      Surgical Procedure:

      Uterine conservation required multidisciplinary team including the obstetrician, anasethetist and urologist in certain cases.

      1. Preoperative prophylactic antibiotic was given to study cases prior to skin incision tio avoid postoperative endometritis in the form of 2gm ampicillin. (ACOG, 2011)
      2. Preoperative blood cross matching as availability of adequate blood was mandatory.
      3. Operative Steps:

        • Elective CS at 36 weeks to 37 weeks was done.
        • Prior to delivery, two large bore venous lines were placed.
        • General anasethia was recommended.
        • Foley catheter was inserted.
        • Sterilization by povidone- iodine scrub and toweling.
        • Midline incision was done as it made field obvious.
        • Incision of subcutaneous tissue and rectus sheath.
        • Separation of two recti.
        • Classical CS (vertical incision in the upper uterine segment) or high transverse uterine incision was done to decrease haemorrhage through placental bed and to avoid urinary bladder injury as it may be adherent to lower uterine segment in some cases.
        • Delievery of the fetus by gental fundal pressure.
        • At the delivery of the fetus 10 UI of oxytocin IV was injected to help uterus to contract and avoid postpartum atony and to decrease blood loss during delivery.
        • No attempt to the deliver the placenta
        • Exteriorization of uterus including placenta clamped.
        • Two corners of the uterine incision, and the superior and inferior lips, were clamped immediately by four clamps.
        • Opening of the broad ligament via round ligament division and ligation.
        • Gentle dissection of the bladder from the uterus was performed from lateral aspect to medially.
        • Bilateral uterine artery clamping at below the placental bed
        • Continue gentle dissection the remaining adherent part of the urinary bladder
        • Gentle attempt to delierve the placenta by gentle traction on clamp.
        • If the placenta was delievered, bilateral uterine artery ligation at multiple levels and multiple square compression sutures (if needed) to control pacental bleeding bed .
        • If the placenta was not delievered we did segmental ressection of lower uterine segment including the placenta. The affected area, once excised can be repaired and the patient was treated as though she had a classical cesarean delivery.
        • Intraperitoneal drain was inserted for early detection of intraperitoneal hemorrhage or urine leak in case of cystotomy repair or possible ureteric injury.
        • The amount of blood loss within 24 h after surgery was measured by the weight of blood-soaked disposable hip pads minus its own weight.
        • Transfusion must include not only packed red blood cells (PRBC), but also fresh frozen plasma and/or cryoprecipitate to maintain in a 2:1 ratio to prevent dillutional coagulopathy

      Outcome variables:

      1. Demographic data e.g age, parity, body mass index (BMI).
      2. Amount of blood loss by measuring Hb preoperatively and after blood transfusion.
      3. Amount of blood loss intraoperative via amount and number of tampons used.
      4. Amount of blood and blood products transfusion.
      5. Hemeostasis and analegesia postoperatively.
      6. Duration of ambulation and audible intestinal sounds.
      7. Follow up of nishe at placental bed after 6 weeks via color Doppler Ultrasoumd.
      8. Intraoperative complications e.g urinary bladder injury, ureteric injury.
      9. Postoperative complications e.g ileus, sepsis.
      10. Need for conversion to hysterectomy.
02

Conditions studied

  • Placenta Accreta

Browse trials for

03

In context

Placenta Accreta

150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.

This study's enrollment of 60 is below the median of 70 across 67 interventional studies indexed under Placenta Accreta.

Browse Placenta Accreta studies →

Lead sponsor

Menoufia Obstetrics and Gynecology Group is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 1- Age between 20 - 40 years old. 2- Gestational age between 28 - 38 weeks. 3- Any patient diagnosed as placenta previa with ultrasound criteria of accretion.

    • Criteria of accretion by Colour Doppler ultrasound include: (Berkley et al., 2013).

      1. The presence of irregular shaped placental lacunae within the placenta.
      2. Thinning of myometrium overlying the placenta.
      3. Absence of retroplacental 'non-lucent line'.
      4. Protrusion of the placenta into the bladder.
      5. Increased vascularity of the uterine serosa-bladder interface.
      6. Turbulent blood flow through the lacunae on Doppler ultrasonography.

Exclusion criteria

Exclusion Criteria:

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Other
    Placenta Accreta patients

    of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.

    Procedure: Novel Technique of Placenta Accreta in Menoufia University Hospital

Interventions

  • ProcedureNovel Technique of Placenta Accreta in Menoufia University Hospital

    * Classical CS to decrease haemorrhage from placental bed. * Delievery of the fetus. * At the delivery 10 UI of oxytocin IV will be injected. * The placenta is not attempted to be delievered. * Opening of the broad ligament via round ligament division and ligation. * Gentle dissection of the urinary bladder from lateral to medial. * Bilateral uterine artery clamping at low level below the placental bed . * Gentle attempt to deliver The placenta. * If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision. * If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta . * Intraperitoneal drain insertion.

06

What researchers measure

Primary outcomes

  1. Outcome variables: Need for conversion to hysterectomy.

    control of bleeding and need for removal of uterus.

    Time frame: 30- 90 minutes

  2. Blood Loss.

    Amount of blood loss ,Number of packed red blood cells and blood products transfusion.

    Time frame: During operation and 24 hours postpartum.

Secondary outcomes

  1. Intraoperative complications

    urinary bladder injury, ureteric injury. Postoperative complications e.g ileus, sepsis

    Time frame: During operation and postpartum period.

07

Study locations

2 sites
  • Menoufia University hospital
    Shibīn Al Kawm, Menoufia 11111, Egypt
  • Hamed Elsayed Ellakwa
    Shibīn Al Kawm, 11111, Egypt
08

References and documents

Publications

  • Elkhouly NI, Solyman AE, Anter ME, Sanad ZF, El Ghazaly AN, Ellakwa HE. A new conservative surgical approach for placenta accreta spectrum in a low-resource setting. J Matern Fetal Neonatal Med. 2022 Aug;35(16):3076-3082. doi: 10.1080/14767058.2020.1808616. Epub 2020 Aug 25. PubMed 32842821 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2019, 12 months.

Of 45 non-industry interventional studies with no phase under Placenta Accreta, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's 12 months is below that.

Counting every sponsor, half of 45 studies reached it within 19 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 13, 2019
StartActual
Nov 1, 2018
Primary completionActual
Nov 1, 2019
CompletionActual
Nov 1, 2019
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04161521
Lead sponsor
Menoufia Obstetrics and Gynecology Group
Responsible party
Dr Hamed Ellakwa (Professor Hamed Ellakwa, Menoufia Obstetrics and Gynecology Group) — Principal investigator
First posted
Nov 13, 2019
Start date
Nov 1, 2018
Primary completion
Nov 1, 2019
Completion
Nov 1, 2019
Last update
Nov 13, 2019

Study contacts

Hamed E Ellakwa
study director · Menoufia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion